Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01573039
Other study ID # CAPPesq 0045/11
Secondary ID
Status Completed
Phase N/A
First received April 4, 2012
Last updated April 3, 2014
Start date November 2011
Est. completion date July 2013

Study information

Verified date January 2013
Source University of Sao Paulo General Hospital
Contact n/a
Is FDA regulated No
Health authority Brazil: National Committee of Ethics in Research
Study type Observational

Clinical Trial Summary

CMV disease is a challenge to the success of renal transplantation. Recently, the investigators analyzed data from 792 renal transplant recipients performed at our hospital between 1999 and 2005. After the usual exclusions, 663 patients were analyzed. This population showed that the incidence of CMV disease is stable and occurs in approximately 20-22% of all patients and invasive disease in approximately 5% every year. In seronegative patients and those receiving anti-lymphocyte (AL), CMV prophylaxis, done with ganciclovir for 90 days is our routine and in the majority of transplant centers. In seropositive patients without associated risk factors (such as the use of AL) universal prophylaxis is not done. Rather, in this group, early diagnosis, by detection of antigenemia or viremia by quantitative PCR, is performed in patients who show symptoms compatible with CMV disease. In the investigators analysis the incidence of CMV disease in seropositive patients is around 16%. These patients are usually hospitalized and treated with GCV IV for 14-21 days. This leads to an additional costs of admissions, biopsies for the diagnosis of disease invasion, etc. Besides these costs, the survival of the grafts in the long run is lower in patients with CMV disease than in those without CMV, particularly when associated with acute rejection. In recent years, monitoring of viremia (PCR / antigenemia) and preemptive treatment when it reaches substantial values, have increasingly been suggested. Patients in whom the detection of viremia in progressive values is detected would be treated as outpatients before the disease develops. To turn this hypothesis into reality, there is an urgent need to define cutoff values for CMV-PCR in the detection of developing CMV disease.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date July 2013
Est. primary completion date November 2012
Accepts healthy volunteers No
Gender Both
Age group 14 Years to 75 Years
Eligibility Inclusion Criteria:

- Patients over 14 years and younger than 75 years

- Seropositive for CMV (IgG)

- Kidney transplant recipients

Exclusion Criteria:

- Patients who received anti-lymphocyte induction

- Patients with organ transplants double

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Brazil Hospital das Clinicas - Faculdade de Medicina da Universidade de São Paulo Sao Paulo

Sponsors (1)

Lead Sponsor Collaborator
University of Sao Paulo General Hospital

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Establish a cutoff for viremia, antigenemia detected by PCR and quantitative-to event for CMV disease. Day 0,7,14,21,28,35,42,56,63, 70,77,84,91,98, 105,112,120 Yes
See also
  Status Clinical Trial Phase
Terminated NCT02439957 - A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Phase 3
Terminated NCT02439970 - A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease Phase 3
Active, not recruiting NCT04904614 - Letermovir Use in Heart Transplant Recipients Phase 4
Completed NCT01509404 - Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection Phase 4
Completed NCT04225923 - A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection Phase 2
Completed NCT00907686 - TT-CMV Observational Birth Cohort Study N/A
Completed NCT04129398 - MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) Phase 3
Recruiting NCT00828503 - Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients Phase 2